Idacta mAb INT-001 represents a interesting medicinal approach for treating selected hematologic tumors. The antibody shows an unique process of function, mainly targeting the CD38 antigen, a membrane molecule expressed often on various blood-forming cells. Preliminary investigational studies see… Read More

Lodelcizumab, a recently discovered monoclonal antigen, represents a promising solution in the fight against recurrent migraines. Unlike many current therapies that focus pain itself, lodelcizumab specifically inhibits CGRP, a crucial protein involved in migraine onset. This unique process of fun… Read More

Milatuzumab, previously known as MEDI-115, represents a unique approach targeting human leukemia-lymphoma surface protein 1 (hLL1), also identifiable by the chemical 899796-83-9. This monoclonal antibody demonstrates high binding to hLL1, a protein frequently upregulated in several cancers of the… Read More

Compound E, chemically designated as 209986-17-4 (CAS), represents a significant study within the field of Alzheimer's disease research. This γ-secretase inhibitor was initially developed as a potential therapeutic treatment aimed at reducing the production of amyloid-beta peptides, which are bel… Read More